Lymphocytes, cytokines, inflammation, and immune trafficking

Current Opinion in Rheumatology

Volumn 9, Issue 5, 1997, Pages 380-386

  Tsokos, George C ^a   Kovacs, Birgit ^a   Liossis, Stamatis Nick C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CALCIUM ION; CYTOKINE; DNA ANTIBODY; FAS ANTIGEN; GLYCOPROTEIN GP 39; INTERLEUKIN 10; LYMPHOCYTE RECEPTOR; MEMBRANE ANTIGEN; TYROSINE;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CALCIUM CELL LEVEL; CELL DEATH; CHROMOSOME 1Q; DISEASE ACTIVITY; ETHNOLOGY; ETIOLOGY; GENETIC LINKAGE; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; KERATINOCYTE; LYMPHOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; CYTOKINES; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES;

EID: 0030821695     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199709000-00002     Document Type: Review

References (57)

1. Via CS, Handwerger BS: B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993, 5:570-574.
2. Tsokos GC: Biochemical and molecular abnormalities in systemic lupus erythematosus. Clin Exp Rheumatol 1992, 9:533-539.
3. Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg AM: NIH conference: systemic lupus erythematosus. Ann Intern Med 1991, 115:548-559.
4. Tsokos GC: Overview of cellular Immune function in systemic lupus erythematosus. In Systemic Lupus Erythematosus, edn 2. Edited by Lahita RG. New York: Churchill Livingstone; 1992:15-50.
5. Tsokos GC: Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1994, 6:461-467.
6. Tsokos GC: Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1995, 7:376-383.
7. Tsokos GC: Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1996, 8:395-402.
8. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MGE, Kimberly RP: FcgammaRIIA alleles are heritable risk factors for lupus nephritis. J Clin Invest 1996, 97:1348-1354.
9. Kimberly RP, Salmon JE, Edberg JC: Receptors for immunoglobulin G: molecular diversity and implications for disease. Arthritis Rheum 1995, 38:306-314.
10. Huang DF, Siminovich KA, Liu XY, Olee T, Olsen NJ, Berry C, Carson DA, Chen PP: Population and family studies of three disease-related polymorphic genes in systemic lupus erythematosus. J Clin Invest 1995, 95:1766-1772.
11. Theofilopoulos AN: The basis of autoimmunity. Part II: genetic predisposition. Immunol Today 1995, 15:150-158.
12. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, Wallace DJ, Kitridou RC, Chen SL, Shen N, et al.: Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997, 99:725-731. The distal end of chromosome 1 in murine models of lupus has been linked to manifestations of SLE. In this study, the human homologous region was analyzed using the microsatellite marker technique in 52 lupus-affected sibling pairs. A strong linkage was identified for the distal region 1q41-q42, which was unaffected even by ethnic differences among the patients in the study group. Even though the number of participating patient pairs did not have the statistical power to exclude localization of a susceptibility locus to other regions more proximal on chromosome 1, it certainly has enough power to localize a disease-susceptibility locus on this specific human chromosome.
13. Kotzin BL: Susceptibility loci for lupus: a guiding light from murine models [editorial]? J Clin Invest 1997, 99:557-558.
14. Mondino A, Khoruts A, Jenkins AK: The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci U S A 1990, 87:7020-7024.
15. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK: Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995, 95:531-541.
16. Mohan C, Datta SK: Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995, 77:209-220.
17. Datta SK, Kaliyaperumal A, Desai-Mehta A: T cells of lupus and molecular targets for immunotherapy. J Clin Immunol 1997, 17:11-20.
18. Steinman L: A few autoreactive cells in an autoimmune infiltrate control a vast population of non-specific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A 1996, 93:2253-2256.
19. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptor. Cell 1994, 76:263-274.
20. Cambier JC, Pleiman CM, Clark MR: Signal transduction by the B cell receptor and its coreceptors. Annu Rev Immunol 1994, 12:457-486.
21. Coggeshall KM, McHugh JC, Altman A: Predominant expression and activation-induced tyrosine phosphorylation of phospholipase C-γ2 in B lymphocytes. Proc Natl Acad Sci U S A 1992, 89:5660-5664.
22. Vassilopoulos D, Kovacs B, Tsokos GC: TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995, 137:2269-2281.
23. 2+ responses, which were associated with increased production of tyrosyl phosphorylated proteins. These findings were disease specific, disease activity independent, and unrelated to clinical manifestations or treatment, implying a possible pathogenic significance for SLE B cells.
24. Sloan-Lancaster J, Steinberg TH, Allen PM: Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 1996, 184:1525-1530.
25. Harding FA, McArthur JG, Gross JA, Raulet DH: CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356:607-609.
26. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 1996, 184:365-376.
27. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
28. Sfikakis PP, Oglesby R, Sfikakis P, Tsokos GC: B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Clin Exp Immunol 1994, 96:8-14.
29. Tsokos GC, Kovacs B, Sfikakis PP, Theocharis S, Vogelgesang SA, Via CS: Defective antigen-presenting cell function in patients with systemic lupus erythematosus: role of the B7-1 (CD80) costimulatory molecule. Arthritis Rheum 1996, 39:600-609.
30. Hollenbaugh D, Ochs HD, Noelle RJ, Ledbetter JA, Aruffo A: The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 1994, 138:23-37.
31. Koshy M, Berger D, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837. The expression, regulation, and function of the CD40 ligand on SLE lymphocytes-which is part of the very important pair of costimulatory molecules CD40 and CD40 ligand-were addressed in this study. Increased and prolonged expression of the CD40 ligand was shown on lupus T cells compared with normal T cells. CD40 ligand was elegantly shown to retain functional properties using as a measure the increased induced upregulation of B7-1 on a B-cell line.
32. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063-2073. This study not only demonstrates abnormalities in the expression and regulation of the CD40 ligand on lupus T cells but also reveals the surprising finding that B cells from patients with SLE are highly and intensely positive for CD40 ligand. The expression of CD40 ligand on T cells was related to disease activity, but the regulation of this molecule was not only abnormal but also, and more importantly, disease activity independent. The appearance of the CD40 ligand on the surface of peripheral B cells was verified by polymerase chain reaction analysis, and the functionality of the molecule was ingeniously shown by inhibition of anti-DNA antibody production using an anti-CD40 ligand monoclonal antibody.
33. Wilson HA, Greenblatt D, Taylor CW, Putney JW, Tsien RY, Finkelman FD, Chused TM: The B lymphocyte calcium response to anti-Ig is diminished by membrane immunoglobulin crosslinkage to the Fcγ receptor. J Immunol 1987, 138:1712-1718.
34. Frank MM, Hamburger MI, Lawley TJ, et al.: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1993, 300:518-523.
35. Koretzky GA: Rote of the CD45 tyrosine phosphatase in signal transduction in the immune system. FASEB J 1993, 7:420-426.
36. Czyzyk J, Fernsten P, Shaw M, Winfield JB: Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1996, 39:592-599.
37. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P: Role of interteukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
38. Hagiwara E, Gourley MF, Lee S, Klinman DM: Disease severity in patients with systemic lupus erythematosus correlates with increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379-385.
39. Mysler E, Bini P, Ramos P, Friedman SM, Krammer PH, Elkon KB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994, 93:1029-1034.
40. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S: Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994, 73:109-114.
41. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994, 152:3685-3692.
42. Kovacs B, Liossis SNC, Dennis GJ, Tsokos GC: Increased expression of functional Fas ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997, in press.
43. Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997, 40:306-317.
44. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome: an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996, 335:1643-1649.
45. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, Fisher A: Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996, 348:719-723.
46. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996, 98:1107-1113.
47. Kovacs B, Szentendrei T, Bednarek JM, Pierson MC, Mountz JD, Vogelgesang SA, Tsokos GC: Persistent expression of a soluble form of Fas/APO-1 in continuously activated T-cells from a patient with SLE. Clin Exp Rheumatol 1997, 15:19-23.
48. Reap EA, Leslie D, Abrahams M, Eisenberg RA, Cohen PL: Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice. J Immunol 1995, 154:936-943.
49. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993, 177:1367-1381.
50. Tucek-Szabo CL, Andjelik S, Lacy E, Elkon KB, Nikolic-Zugic J: Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis: activation-induced death can occur without Fas receptor. J Immunol 1996, 156:192-200.
51. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-351.
52. Jacob CO, McDevitt HO: Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 1988, 331:356-358.
53. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990, 87:1233-1237.
54. Utz PJ, Hottelet M, Schur PH, Anderson P: Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997, 185:843-854.
55. Stohl W, Elliott JE, Hamilton AS, Deapen DM, Mack TM, Horwitz DA: Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 1996, 39:1840-1851. Peripheral blood mononuclear cells from a large number of patients with SLE and normal controls were polyclonally expanded, and the recovery of CD56+ T and non-T cells was determined. Significantly fewer CD56+ cells were recovered, and the cytolytic activity of this population was also found to be significantly decreased. This was not due to a lack of precursors but rather was the effect of impaired maturation of existing cells into the cytolytic effectors examined. More importantly, this effect was unrelated to disease activity or treatment and extended to the unaffected by SLE monozygotic twins of lupus patients. These data suggest that impaired generation of cytolytic CD56+ effectors may be inherent to the disease.
56. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
57. Casciola-Rosen LA, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1996, 93:1624-1629.